Saizen
Saizen contains somatropin, which is a recombinant human growth hormone (rhGH) produced using recombinant DNA technology. It is identical in amino acid sequence and structure to the pituitary-derived human growth hormone. It stimulates linear growth, skeletal growth, and plays a major role in metabolism, including increasing protein synthesis, mobilizing fat stores, and influencing carbohydrate metabolism.
Dosage by Body Weight
Saizen must be prescribed and monitored by a specialist. Dosage is highly individualized and calculated based on the patient's body weight or body surface area, response to therapy, and the specific indication. It is administered daily via subcutaneous injection, usually in the evening. Injection sites must be rotated to prevent local lipoatrophy.
- Body Weight
- Below 5 kg
- Dose
- Not routine
- Frequency
- Use only if prescribed by a pediatric endocrinologist
- Tracking Notes
- Growth hormone therapy is rarely initiated in infants weighing less than 5 kg. If prescribed, dosing is extremely precise and tailored strictly to metabolic and clinical tolerance.
- Body Weight
- 5-7 kg
- Dose
- 0.15 mg to 0.25 mg daily
- Frequency
- Once daily (subcutaneous)
- Tracking Notes
- Calculated based on typical pediatric growth hormone deficiency dosage (approx. 0.025 to 0.035 mg/kg/day). Higher target ranges may apply for Turner syndrome or renal failure.
- Body Weight
- 8-10 kg
- Dose
- 0.24 mg to 0.35 mg daily
- Frequency
- Once daily (subcutaneous)
- Tracking Notes
- Doses should be administered in the evening to mimic physiological GH secretion patterns. Regularly monitor thyroid function and glucose tolerance.
- Body Weight
- 11-15 kg
- Dose
- 0.33 mg to 0.52 mg daily
- Frequency
- Once daily (subcutaneous)
- Tracking Notes
- Adjustment in dose may be needed based on clinical response, side effects, and serum Insulin-like Growth Factor-1 (IGF-1) concentrations.
- Body Weight
- 16-20 kg
- Dose
- 0.48 mg to 0.70 mg daily
- Frequency
- Once daily (subcutaneous)
- Tracking Notes
- Injection sites must be rotated daily. Regular pediatric endocrinology follow-ups are required to evaluate growth speed and bone maturation.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine | Use only if prescribed by a pediatric endocrinologist | Growth hormone therapy is rarely initiated in infants weighing less than 5 kg. If prescribed, dosing is extremely precise and tailored strictly to metabolic and clinical tolerance. |
| 5-7 kg | 0.15 mg to 0.25 mg daily | Once daily (subcutaneous) | Calculated based on typical pediatric growth hormone deficiency dosage (approx. 0.025 to 0.035 mg/kg/day). Higher target ranges may apply for Turner syndrome or renal failure. |
| 8-10 kg | 0.24 mg to 0.35 mg daily | Once daily (subcutaneous) | Doses should be administered in the evening to mimic physiological GH secretion patterns. Regularly monitor thyroid function and glucose tolerance. |
| 11-15 kg | 0.33 mg to 0.52 mg daily | Once daily (subcutaneous) | Adjustment in dose may be needed based on clinical response, side effects, and serum Insulin-like Growth Factor-1 (IGF-1) concentrations. |
| 16-20 kg | 0.48 mg to 0.70 mg daily | Once daily (subcutaneous) | Injection sites must be rotated daily. Regular pediatric endocrinology follow-ups are required to evaluate growth speed and bone maturation. |
Formulation
Purpose
Treatment of growth hormone deficiency (GHD) in children and adults, growth failure in girls with Turner syndrome, growth failure in children due to chronic renal insufficiency, and growth failure in children born small for gestational age (SGA).
Generic Name
SomatropinScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.